Detalhe da pesquisa
1.
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Br J Clin Pharmacol
; 75(5): 1240-54, 2013 May.
Artigo
Inglês
| MEDLINE | ID: mdl-23013236
2.
Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Am J Ther
; 16(6): 487-95, 2009.
Artigo
Inglês
| MEDLINE | ID: mdl-19940609
3.
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
Diabetes
; 67(6): 1105-1112, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29545266
4.
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
Clin Cancer Res
; 8(5): 1065-72, 2002 May.
Artigo
Inglês
| MEDLINE | ID: mdl-12006520
5.
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
Clin Cancer Res
; 10(16): 5447-54, 2004 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-15328183